Article Figures & Data
Figures
- FIGURE 1.
Average values for activity corresponding to unmetabolized parent compound in plasma as function of time for 0.05, 0.015, and 0.1 mg of ketanserin per kilogram for entire study (A), first 30 min after injection (B), and 70–470 min after injection (C). All values are decay corrected to injection time and normalized with injected activity. Values in A include SD.
- FIGURE 2.
Scatterplots of SRTM vs. TR measurements: BPpre vs. SUR180 (A), BPpost vs. SUR400 (B), and %DisplSRTM vs. %DisplTR (C).
- FIGURE 3.
Coregistered MRI/SPECT images from 3 representative healthy volunteers, each receiving a different ketanserin dose. Baseline scans at 180 min after injection are on left; postketanserin scans at 400 min after injection are on right. Ketanserin doses are 0.015 mg/kg (A), 0.05 mg/kg (B), and 0.1 mg/kg (C). Gradual dose-dependent displacement is seen. (Reprinted from (9 [Fig. 19]) with the kind permission of Springer Science and Business Media.)
- FIGURE 4.
Mean SUR values over time for all cerebral regions studied from each pair of subjects on same ketanserin dose.
- FIGURE 5.
Time–activity curves of cerebellum and occipital calcarine region, with corresponding SRTM fit, from subject receiving highest ketanserin dose, 0.1 mg/kg. Slight and transient decrease in cerebellum uptake is seen from 210 to 240 min, when largest decrease in cortical time–activity curve occurred. Cerebellum slope recovered completely by 270 min.
- FIGURE 6.
Relationship between ketanserin plasma concentration and 123I-R91150 displacement using SRTM, for all cortical regions (A); using TR, for all cortical regions (B); and comparing model fit for both SRTM and TR in representative region (prefrontal cortex) (C).
Tables
- TABLE 1
BP Values Calculated from SRTM, and SUR Calculated from TR, with Corresponding Percentages of 123I-R91150 Displacement for Each Region in Each Subject at the 3 Ketanserin Doses
ROI Subject BPpre BPpost SUR180 SUR400 %DisplSRTM %DisplTR 0.1 mg/kg Orbitofrontal 1 0.44 0.19 0.55 0.14 57.1 74.8 2 0.81 0.29 1.00 0.26 64.6 74.1 Prefrontal 1 0.41 0.04 0.49 0.02 89.9 95.1 2 0.68 0.11 0.81 0.11 83.3 87.0 Superior frontal 1 0.29 0.01 0.35 0.00 95.4 101.2 2 0.63 0.10 0.72 0.09 84.9 87.2 Calcarine occipital 1 0.40 0.13 0.48 0.13 68.7 71.9 2 0.71 0.13 0.78 0.13 82.2 82.9 Lateral occipital 1 0.42 0.08 0.48 0.08 79.8 82.9 2 0.49 0.07 0.57 0.03 86.0 94.0 Temporal 1 0.44 0.11 0.47 0.09 74.6 81.3 2 0.76 0.22 0.87 0.20 71.5 77.5 Parietal 1 0.27 0.03 0.28 0.02 89.8 91.7 2 0.62 0.13 0.67 0.14 79.6 79.5 0.05 mg/kg Orbitofrontal 3 0.37 0.18 0.44 0.19 51.7 56.7 4 0.56 0.27 0.57 0.24 52.0 58.6 Prefrontal 3 0.29 0.05 0.35 0.06 82.5 82.6 4 0.51 0.20 0.54 0.17 61.1 67.8 Superior frontal 3 0.27 0.04 0.33 0.02 84.5 92.5 4 0.40 0.15 0.39 0.12 63.5 70.4 Calcarine occipital 3 0.41 0.15 0.46 0.09 63.5 81.4 4 0.42 0.13 0.42 0.13 69.8 69.4 Lateral occipital 3 0.25 0.10 0.28 0.11 60.7 62.5 4 0.46 0.04 0.45 0.09 91.4 79.6 Temporal 3 0.32 0.15 0.39 0.11 53.2 70.9 4 0.46 0.16 0.47 0.19 65.8 59.2 Parietal 3 0.17 0.04 0.21 −0.01 76.5 102.8 4 0.42 0.14 0.40 0.12 65.5 71.5 0.015 mg/kg Orbitofrontal 5 0.35 0.32 0.38 0.33 7.7 13.8 6 0.70 0.44 0.65 0.51 36.4 20.9 Prefrontal 5 0.27 0.23 0.33 0.24 17.0 27.8 6 0.48 0.27 0.49 0.32 43.6 35.4 Superior frontal 5 0.23 0.17 0.28 0.18 25.3 34.8 6 0.36 0.21 0.42 0.23 42.4 47.0 Calcarine occipital 5 0.28 0.20 0.33 0.21 26.8 37.6 6 0.45 0.28 0.54 0.30 38.2 44.0 Lateral occipital 5 0.18 0.13 0.16 0.12 27.6 22.8 6 0.37 0.17 0.37 0.19 54.5 48.5 Temporal 5 0.28 0.24 0.31 0.25 14.8 19.0 6 0.64 0.33 0.60 0.41 48.0 31.1 Parietal 5 0.27 0.20 0.30 0.21 25.8 29.6 6 0.40 0.20 0.42 0.25 50.8 40.5 SRTM TR ROI Displmax EC50 γ Displmax EC50 γ Orbitofrontal 82 7.1 1.2 82 6.5 2.2 Prefrontal 100 5.6 1.5 100 5.3 1.8 Superior frontal 100 5.1 1.6 100 4.2 1.6 Calcarine occipital 92 5.1 1.3 86 3.4 1.5 Lateral occipital 100 4.2 1.1 100 5.1 1.4 Temporal 100 6.9 1.0 92 6.0 1.7 Parietal 100 4.8 1.2 93 4.2 2.2 Population means 99.8 5.6 1.3 98.6 5.0 1.8
Jump to section
Related Articles
Cited By...
- The Influence of Morphine on Cerebral 5-HT2A Availability in Dogs: a SPECT Study
- Contribution of SPECT Measurements of D2 and 5-HT2A Occupancy to the Clinical Development of the Antipsychotic SB-773812
- Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1--Pseudoequilibrium Interval and Quantification Methods